



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## enzalutamide

October 21, 2014

### **Non-proprietary Name**

enzalutamide

### **Safety measure**

Precautions should be revised in the package insert.

In Clinically significant adverse reactions subsection of Adverse reactions section, the following texts should be added (underlined parts are revised):

#### Thrombocytopenia:

Thrombocytopenia may occur. Patients should be carefully monitored. If any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.